Perhaps PRMT5 and MAT2A inhibitors combined with other treatment methods (immunotherapy, chemotherapy, and molecularly targeted therapies) could be considered as first-line therapy for patients with selected cancers. The gene discussed is MAT2A; the disease is cancer.